Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 2042-2048

  Lapi, Suzanne E ^a   Wahnishe, Hilla ^a   Pham, David ^a   Wu, Lisa Y ^b   Nedrow Byers, Jessie R ^b   Liu, Tiancheng ^b   Vejdani, Kaveh ^a   VanBrocklin, Henry F ^a   Berkman, Clifford E ^b,c   Jones, Ella F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Cancer Targeted Technology   (United States)

Author keywords

18F; Molecular imaging; PET; Phosphoramidate; Prostate cancer; PSMA; Radiopharmaceuticals

Indexed keywords

ANTINEOPLASTIC AGENT; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; S 2 ((2 (S 4 (4 FLUOROBENZAMIDO) 4 CARBOXYBUTANAMIDO) S 2 CARBOXYETHOXY)HYDROXYPHOSPHORYL AMINO)PENTANEDIOIC ACID F 18; UNCLASSIFIED DRUG; AMIDE; DIAGNOSTIC AGENT; FLUORINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PEPTIDE; PHOSPHORAMIDIC ACID; PHOSPHORIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; KIDNEY TUBULE ABSORPTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DRUG ANTAGONISM; ISOTOPE LABELING; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; TUMOR CELL LINE;

AMIDES; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLUORINE RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; ISOTOPE LABELING; MALE; MICE; PEPTIDES; PHOSPHORIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 73349142047     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066589     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Speight JL, Roach M, III. Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. 2007;25:987-995.
3. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91: 528-539.
4. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res. 2004;10:3943-3953.
5. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028.
6. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933-7943.
7. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
8. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-1451.
9. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology. 1997;49:104-112.
10. Barinka C, Rinnova M, Sacha P, et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem. 2002;80:477-487.
11. Mallari JP, Choy CJ, Hu Y, et al. Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorg Med Chem. 2004;12:6011-6020.
12. Wu LY, Anderson MO, Toriyabe Y, et al. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem. 2007;15:7434-7443.
13. Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry. 2008.
14. Liu T, Wu LY, Kazak M, Berkman CE. Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate. 2008;68:955-964.
15. 18F]fluorobenzoate. Appl Radiat Isot. 2003;59:43-48.
16. Lapatsanis L, Milas G, Froussios K, Kolovos M. N-2,2,2- (trichloroethoxycarbonyl)-L-amino acids and synthesis of N-(9- fluoroenymethoxycarbonyl)-L-amino acids involving succininidoxy anion as a leaving group in amino acid protection. Synthesis. 1983;8:671-673.
17. 18F]SFB). Appl Radiat Isot. 2005;63:329-332.
18. Anderson MO, Wu LY, Santiago NM, et al. Substrate specificity of prostatespecific membrane antigen. Bioorg Med Chem. 2007;15:6678-6686.
19. Maung J, Mallari JP, Girtsman TA, et al. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem. 2004;12:4969-4979.
20. Hermanson GT. Bioconjugation Techniques. San Diego, CA: Academic Press, Inc.; 1996.
21. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
22. Aggarwal S, Ricklis RM, Williams SA, Denmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate. 2006;66:903-910.
23. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer. 2005;116:415-421.
24. Klein EA. Management of Prostate Cancer. 2nd ed. Totowa, NJ: Humana Press; 2004.
25. Sodee DB, Ellis RJ, Samuels MA, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998;37:140-148.